Composition for preventing hair loss and promoting hair growth

Abstract

The present invention relates to a composition for preventing hair loss and promoting hair growth, which contains an ingredient that induces new hair growth or promotes hair growth. The composition for preventing hair loss and promoting hair growth of the present invention shortens the period during which hair grows from the telogen phase to the anagen phase, thereby promoting hair growth and delaying the transition to the catagen phase, and is therefore highly effective in preventing hair loss and promoting hair growth.

Description

[Technical Field]

[0001] The present invention relates to a composition for promoting hair growth, and more particularly to a composition for preventing hair loss and promoting hair growth, which contains an ingredient that induces new hair growth or promotes hair growth. [Background technology]

[0002] As interest in beauty has grown in recent years, hair has become an important part of our lives. Hair is a thin, keratinized structure that grows on the surface of the skin. It functions as a cushion against external shocks, protecting the body from external stimuli such as direct sunlight, cold, friction, and danger, and expelling harmful heavy metals such as arsenic, mercury, and zinc. In recent years, hair has also become a cosmetic and decorative feature. However, the number of people experiencing hair loss is increasing due to various factors, including changes in diet and increased internal and external stress. While genetic factors are known to be the most common cause of hair loss, as mentioned above, increased social stress, environmental pollution, frequent perms and hair coloring, and improper scalp care are also cited as contributing factors.

[0003] Humans have approximately 100,000 to 150,000 hairs, each with its own distinct growth cycle. The hair growth cycle is divided into three stages: the anagen stage, where hair grows most actively; the catagen stage, where hair begins to degenerate; and the telogen stage, where hair growth stops or the hair goes into rest.

[0004] In regulating this hair growth cycle, the activity of dermal papilla cells and outer root sheath cells containing hair follicle stem cells, as well as the various cytokines and growth factors produced by these cells, are known to play important roles. For example, DKK-1 (Dickkopf-1) plays an important role in inhibiting hair follicle growth and death (J Invest. Dermatol, 2008:128(2)). Meanwhile, hair follicle regeneration and stem cell activation are required for cyclical hair growth, and this is known to be achieved by the production and activation of Wnt / β-catenin (Nature 2007:447(7142)).

[0005] Alopecia generally refers to the abnormal increase in hair loss due to a decrease in the proportion of hairs in the anagen phase and an increase in hairs in the catagen or telogen phase. Normal individuals have a large proportion of hairs in the anagen phase, while individuals with alopecia have a large proportion of hairs in the telogen phase, resulting in visible hair loss. Alopecia is characterized by hair miniaturization. As hair loss progresses, the anagen phase shortens, accelerating the transition to catagen and telogen phases. Subsequently, the volume of the hair papilla decreases, leading to the miniaturization of hair follicles. Therefore, to treat hair loss, it is important to quickly return hair follicles in the telogen phase to the anagen phase and prolong the shortened anagen phase.

[0006] Male pattern baldness, also known as androgenetic alopecia, is the most common type of alopecia among men in their 20s and 30s. This is because androgenetic alopecia is influenced not only by genetic factors, but also by the effects of male hormones and age. Research has shown that the main cause of male pattern baldness is the male hormone testosterone, and it can be classified into various types depending on the shape and progression of the bald spots. Male pattern baldness caused by testosterone occurs when dihydrotestosterone (DHT), generated by the combination of male hormones and the active enzyme 5α-reductase, acts on hair follicles, inhibiting cell division and inhibiting hair growth.

[0007] The type of hair loss varies depending on the distribution of the active enzyme 5α-reductase on the scalp. In the area of ​​the head where the active enzyme is distributed in large amounts, cell division slows down due to the influence of DHT, shortening the hair cycle and causing softening of hair and hair loss. On the other hand, in the areas of the temples and back of the head, the activity of the active enzyme is relatively weak and hair loss is less likely to occur due to the influence of female hormones. Current methods for managing male pattern baldness include hair transplant surgery and drug therapy.

[0008] The causes of hair loss have been suggested to be excess male hormones, excessive sebum secretion, poor blood circulation, decreased scalp function due to peroxides or bacteria, genetic factors, aging, stress, etc., but the cause of hair loss remains unclear to date. In response to these diverse and complex causes of hair loss, currently known hair loss prevention products contain active ingredients that promote blood circulation, strengthen hair root function, moisturize the scalp, prevent dandruff, have antioxidant effects, extend the hair growth phase, or suppress the action of male hormones, but no products have been found to be significantly effective, and side effects are sometimes an issue.

[0009] To date, formulations developed for the treatment or prevention of alopecia include those based on female hormones to promote blood circulation, strengthen hair root function, moisturize the scalp, and suppress male hormones, as well as formulations containing minoxidil, finasteride, and trichosaccharide. Minoxidil (2,4-diamino-6-piperidinopyrimidine-3-oxide), a typical topical hair loss treatment, increases blood flow to the scalp, while finasteride, an oral hair loss treatment, inhibits the activity of 5α-reductase and reduces the production of DHT, an active male hormone. However, these formulations have significant limitations in use due to side effects and precautions. Summary of the Invention [Problem to be solved by the invention]

[0010] An object of the present invention is to provide a composition for preventing hair loss or promoting hair growth that is safe for the human body, has no side effects, and has excellent effects of preventing hair loss or promoting hair growth.

[0011] Another object of the present invention is to provide a hair or scalp product containing the composition for preventing hair loss or promoting hair growth. [Means for solving the problem]

[0012] The present inventors have conducted extensive research to develop a composition that overcomes the problems of conventional hair loss treatments, such as side effects and precautions for use, and that is safe for the human body and effective in promoting hair growth and hair regrowth, without the drawback of hair loss prevention / hair care products having only a slight hair growth promoting effect, and as a result have found that momordin Ic, platycodin D2, polygalacin D, asiaticoside B, bacopaside I, notoginsenoside R2, picfeltarraenin IB, pseudoginsenoside RT5, raddeanin A, vinaginsenoside R4, or ziyuglycoside II We have found that a composition containing II) as an active ingredient is extremely effective in preventing hair loss and promoting hair growth, and have completed the present invention.

[0013] Specifically, the inventors of the present invention have confirmed that each of the active ingredients enhances the activity of dermal papilla cells, promotes mitochondrial activity in dermal papilla cells, promotes the activity of the Wnt / β-catenin signaling pathway, and has the ability to suppress the action of androgen. That is, in vitro experiments have confirmed that each of the active ingredients enhances the activity of dermal papilla cells and amplifies Wnt / β-catenin signaling, thereby playing an important role in the transition from the catagen phase to the catagen phase of the hair cycle. Furthermore, the inventors of the present invention have confirmed that when a composition for treating hair loss containing the active ingredients is administered to a patient suffering from alopecia, it exhibits a significantly excellent effect in improving hair density and thickness. Furthermore, a comparative experiment with the commercially available product minoxidil confirmed that the composition for treating hair loss containing the active ingredients of the present invention has significantly better hair loss prevention and hair growth effects than minoxidil.

[0014] The present invention provides a composition for preventing hair loss or promoting hair growth, comprising one or more active ingredients selected from the group consisting of momordin Ic, platycodin D2, polygalacin D, asiaticoside B, bacopaside I, notoginsenoside R2, picfertalaenin IB, pseudoginsenoside RT5, ladeanin A, vinaginsenoside R4, and diglycoside II.

[0015] In one embodiment, the 11 active ingredients may be derived from plants: momordin Ic is derived from Kochiae Fructus, platycodin D2 is derived from Platycodon grandiflorum (Jacq.) A.DC., polygalacin D is derived from Polygalae radix, asiaticoside B is derived from Centella asiatica (L.) Urb., bacopaside I is derived from Bacopa monnieri (L.) Wettst., notoginsenoside R2 is derived from Panax notoginseng, and picfertalaenin IB is derived from Scrophularia ningpoensis. Hemsl.), the pseudoginsenoside RT5 and vinaginsenoside R4 are derived from Korean ginseng (Ginseng Radix Et Rhizoma), the raddeanin A is derived from Anemone raddeana Regel, and the diglycoside II is derived from Diyu (Sanguisorbae Radix).

[0016] In one embodiment, the momordin Ic may be contained in an amount of 0.00001 to 50% by weight, preferably 0.0001 to 0.1% by weight, based on the total weight of the composition. The platycodin D2 may be contained in an amount of 0.00001 to 50% by weight, preferably 0.0001 to 0.1% by weight, based on the total weight of the composition. The polygalacin D may be contained in an amount of 0.00001 to 50% by weight, preferably 0.0001 to 0.1% by weight, based on the total weight of the composition. The asiaticoside B may be contained in an amount of 0.00001 to 50% by weight, preferably 0.0001 to 0.1% by weight, based on the total weight of the composition. The bacopaside I may be contained in an amount of 0.00001 to 50% by weight, preferably 0.0001 to 0.1% by weight, based on the total weight of the composition. The notoginsenoside R2 may be contained in an amount of 0.00001 to 50% by weight, preferably 0.0001 to 0.1% by weight, based on the total weight of the composition. The picfertalaenin IB may be contained in an amount of 0.00001 to 50% by weight, preferably 0.0001 to 0.1% by weight, based on the total weight of the composition. The pseudoginsenoside RT5 may be contained in an amount of 0.00001 to 50% by weight, preferably 0.0001 to 0.1% by weight, based on the total weight of the composition. The radeanin A may be contained in an amount of 0.00001 to 50% by weight, preferably 0.0001 to 0.1% by weight, based on the total weight of the composition. The vinaginsenoside R4 may be contained in an amount of 0.00001 to 50% by weight, preferably 0.0001 to 0.1% by weight, based on the total weight of the composition. The diglycoside II may be contained in an amount of 0.00001 to 50% by weight, preferably 0.0001 to 0.1% by weight, based on the total weight of the composition.

[0017] When the content of each active ingredient is 0.00001 to 50 wt%, preferably 0.0001 to 0.1 wt%, based on the total weight of the composition, it has been shown in in vitro experiments and clinical studies to have excellent effects in preventing hair loss and promoting hair growth. If the content of the active ingredient is less than 0.00001 wt%, the effect of promoting hair growth is negligible, and if it exceeds 50 wt%, the stability of the formulation is reduced, which is undesirable.

[0018] The present invention also provides a pharmaceutical composition, a quasi-drug composition, a cosmetic composition, or a functional health food composition, comprising the composition for preventing hair loss or promoting hair growth. The composition of the present invention can be formulated into any form that is generally applicable to the skin, preferably in the form of an external preparation for the skin. The composition of the present invention can be prepared in a form that is applicable to the skin, such as a liquid, cream, paste, or solid.

[0019] In the present invention, one or more selected from the group consisting of momordin Ic, platycodin D2, polygalacin D, asiaticoside B, bacopaside I, notoginsenoside R2, picfertalaenin IB, pseudoginsenoside RT5, ladeanin A, vinaginsenoside R4 and diglycoside II may be included in the composition or dosage form as an agent for preventing hair loss or promoting hair growth.

[0020] In one embodiment, when the dosage form of the present invention is liquid, a solvent, solubilizer, or emulsifier may be used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic esters, polyethylene glycol, or sorbitan fatty acid esters. The alcohol refers to one or more alcohols, preferably linear or branched C2-C4 monoalcohols, and more preferably ethanol or isopropanol. In particular, the use of ethanol or isopropanol as a carrier component can facilitate transdermal absorption of the composition for preventing hair loss or promoting hair growth.

[0021] In one embodiment, when the dosage form of the present invention is a paste, cream, or gel, the carrier component may be alcohol, animal oil, vegetable oil, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, etc. Preferably, alcohol can be used, and more preferably, the alcohol may be isopropanol.

[0022] In one embodiment, when the dosage form of the present invention is a powder or spray, the carrier component may be lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder, etc. In particular, when the dosage form is a spray, a propellant such as chlorofluorohydrocarbon, propane / butane, dimethyl ether, etc. may be further included.

[0023] In one embodiment, the composition of the present invention may contain ingredients commonly used in topical preparations for skin, such as momordin Ic, platycodin D2, polygalacin D, asiaticoside B, bacopaside I, notoginsenoside R2, picfertalaenin IB, pseudoginsenoside RT5, ladeanin A, vinaginsenoside R4, and diglycoside II, as well as one or more additives selected from the group consisting of water, surfactants, humectants, lower alcohols, chelating agents, bactericides, antioxidants, preservatives, colorants, and fragrances.

[0024] The present invention also provides a hair or scalp product comprising the composition for preventing hair loss or promoting hair growth. The hair or scalp product may be any one selected from the group consisting of, but not limited to, a hair growth agent, a scalp cleansing agent, a scalp scaling agent, a scalp massage agent, a scalp care agent, a cleanser, a shampoo, a tonic, a hair conditioner, a hair lotion, a gel, a pack, a cream, an essence, a powder, a spray, an oil, a soap, an ointment, a hair styling agent, a hair dye, and a perm.

[0025] In one embodiment, the composition for preventing hair loss or promoting hair growth of the present invention may be prepared in the form of a hair tonic or hair lotion. The composition for promoting hair growth of the present invention may preferably be used by transdermal administration, such as by direct application or sprinkling onto the skin.

[0026] The present invention also provides a functional health food composition comprising the composition for preventing hair loss or promoting hair growth. The functional health food can be prepared by a method commonly used in the art, and may be prepared by adding raw materials and ingredients commonly used in the art. The dosage form of the functional health food can also be prepared without limitation, as long as it is a dosage form recognized as a functional health food. The functional health food of the present invention can be prepared in various dosage forms, and unlike general medicines, it has the advantage of being made from food ingredients, eliminating side effects that can occur with long-term drug use, and is highly portable. The functional health food of the present invention can be taken as an adjuvant to enhance the effects of preventing hair loss and promoting hair growth.

[0027] The present invention also provides a method for preventing hair loss or promoting hair growth, comprising administering to a subject a composition for preventing hair loss or promoting hair growth, the composition comprising one or more active ingredients selected from the group consisting of momordin Ic, platycodin D2, polygalacin D, asiaticoside B, bacopaside I, notoginsenoside R2, picfertalaenin IB, pseudoginsenoside RT5, ladeanin A, vinaginsenoside R4, and diglycoside II.

[0028] The term "administration" as used herein means introducing the composition of the present invention by any suitable method. The administration route of the composition of the present invention can be any common route as long as it can reach the target tissue. The composition of the present invention can be administered transdermally or orally, preferably transdermally, and most preferably by topical application. The frequency of application of the composition of the present invention can be determined according to prescription, need, or desire.

[0029] The amount of the composition of the present invention to be used can be adjusted appropriately depending on the dosage form and individual differences such as age and severity of the lesion, and is generally applied to the scalp in an appropriate amount once or several times a day for a period of one week to several months. In an experimental example of the present invention, Composition 1 for treating hair loss was used five times a week for six months, and it was confirmed that it showed excellent hair growth promoting effects (Experimental Example 5).

[0030] The composition for preventing hair loss and promoting hair growth of the present invention has excellent effects of preventing hair loss and promoting hair growth by shortening the period during which hair transitions from the resting phase to the anagen phase and delaying the transition to the catagen phase. DETAILED DESCRIPTION OF THE INVENTION

[0031] The present invention will be described below with reference to specific examples. However, the examples according to the present invention can be modified in various ways, and the scope of the present invention should not be construed as being limited to the examples described below. The examples of the present invention are provided to more completely explain the present invention to those skilled in the art. [Example]

[0032] Manufacture of hair loss treatment composition (hair tonic) Hair tonic compositions containing momordin Ic, platycodin D2, polygalacin D, asiaticoside B, bacopaside I, notoginsenoside R2, picfertalaenin IB, pseudoginsenoside RT5, ladeanin A, vinaginsenoside R4 or diglycoside II as active ingredients were prepared in accordance with the formulations shown in Table 1 below in a conventional manner as Examples 1 to 11-2.

[0033] The materials and reagents used in the experiments of the present invention were purchased from cosmetic raw material manufacturers and commercial supply companies.

[0034] [Table 1]

[0035] Manufacture of a composition for treating hair loss (hair lotion) Hair lotion compositions containing momordin Ic, platycodin D2, polygalacin D, asiaticoside B, bacopaside I, notoginsenoside R2, picfertalaenin IB, pseudoginsenoside RT5, ladeanin A, vinaginsenoside R4 or diglycoside II as active ingredients were prepared in a conventional manner according to the formulations shown in Table 2 below.

[0036] [Table 2]

[0037] Experimental example 1: Effect of promoting dermal papilla cell activity Human dermal papilla cells (DPCs) were purchased from PromoCell. The DPCs were cultured in DMEM (Hyclone Inc., UT, USA) containing 5% fetal bovine serum (FBS; Gibco, NY, USA), 100 units / mL penicillin, and 100 μg / mL streptomycin at 37°C and 5% CO2. The cultured DPCs were dispensed into a 96-well plate at 3,000 cells / well and cultured in 0.1% serum for 24 hours. The cultured cells were then treated with DMSO (vehicle) diluted 1:1000 in serum-free DMEM as a control, minoxidil 2 μg / ml as a positive control, momordin Ic, platycodin D2, polygalacin D, asiaticoside B, bacopaside I, notoginsenoside R2, picfertalaenin IB, pseudoginsenoside RT5, ladeanin A, vinaginsenoside R4, or diglycoside II as shown in Table 3, and incubated for one day. After incubation, cell proliferation was assessed using the CCK method. CCK-8 was added to the culture medium at a 1:10 concentration and incubated for one hour. After one hour, the absorbance of each well was measured at 450 nm. All experiments were repeated three times, and the average absorbance was calculated. Results were expressed as a percentage of the treated group, with the control group set at 100.

[0038] [Table 3]

[0039] The experimental results confirmed that treatment with momordin Ic, platycodin D2, polygalacin D, asiaticoside B, bacopaside I, notoginsenoside R2, picfertalaenin IB, pseudoginsenoside RT5, ladeanin A, biginsenoside R4, or diglycoside II had an excellent effect of promoting DPC proliferation and enhanced dermal papilla cell activity.

[0040] Experimental Example 2: Effect of promoting mitochondrial activity in dermal papilla cells Human dermal papilla cells (DPCs) were purchased from PromoCell. The DPCs were cultured in DMEM (Hyclone Inc., UT, USA) containing 5% fetal bovine serum (FBS; Gibco, NY, USA), 100 units / mL penicillin, and 100 μg / mL streptomycin at 37°C and 5% CO2. The cultured DPCs were dispensed into a 96-well plate at 3,000 cells / well and cultured in 0.1% serum for 24 hours. The cultured cells were then treated with DMSO (vehicle) diluted 1:1000 in serum-free DMEM as a control, minoxidil 2 μg / ml as a positive control, momordin Ic, asiaticoside B, bacopaside I, notoginsenoside R2, pseudoginsenoside RT5, vinaginsenoside R4, or diglycoside II as shown in Table 4 for one day and then incubated. After incubation, cell proliferation was assessed using the JC-1 method. JC-1 was added to the culture medium at a 1:100 concentration and incubated for one hour. After one hour, fluorescence was measured at 590 nm and 530 nm in each well. All experiments were repeated three times, and the average fluorescence value was calculated. Results were expressed as a percentage of the treated group, with the control group set at 100.

[0041] [Table 4]

[0042] The experimental results showed that treatment with momordin Ic, asiaticoside B, bacopaside I, notoginsenoside R2, pseudoginsenoside RT5, vinaginsenoside R4, or diglycoside II had an excellent effect of promoting mitochondrial activity in dermal papilla cells.

[0043] Experimental Example 3: Effect of regulating dermal papilla cell activation signals (Wnt / β-catenin) Generally, Wnt / β-catenin signaling in the hair papilla is activated during the transition from the catagen phase to the activating phase of the hair growth cycle, i.e., from the time hair begins to grow to the activating phase during hair growth. Furthermore, during the telogen and catagen phases, Wnt / β-catenin signaling weakens or disappears, resulting in hair follicle degeneration and hair loss. Therefore, this experiment confirmed how momordin Ic, platycodin D2, polygalacin D, or pseudoginsenoside RT5 of the present invention contribute to the amplification of Wnt / β-catenin signaling.

[0044] Wnt3a protein was used as a positive control to amplify the Wnt / β-catenin signal, and DMSO was used as a negative control. Approximately 3 × 10 4 Wnt reporter HEK293A cells were seeded into each well and treated with momordin Ic, platycodin D2, polygalacin D, or pseudoginsenoside RT5 according to the present invention, as shown in Table 5. A reporter assay was then performed using a Promega luciferase assay kit (E1960). Wnt / β-catenin promoter activity was measured using a Victor luminometer (PerkinElmer, Waltham, Massachusetts, USA) according to the manufacturer's protocol.

[0045] [Table 5]

[0046] The experimental results showed that treatment with momordin Ic, platycodin D2, polygalacin D, or pseudoginsenoside RT5 had an excellent effect on Wnt signal activation. Therefore, it was confirmed that momordin Ic, platycodin D2, polygalacin D, or pseudoginsenoside RT5 have an excellent effect on promoting hair growth by highly enhancing the activity of the Wnt / β-catenin signaling pathway, which is a hair growth-promoting signal in hair follicle stem cells.

[0047] Experimental Example 4: Antiandrogenic activity evaluation In this experiment, we used a stable cell line derived from the androgen receptor-positive 22Rv1 human prostate cancer cell line, which was permanently transfected with the pGL4.36-MMTV-Luc vector, which contains two androgen response factors and a firefly luciferase reporter gene. This stable cell line was maintained by subculture in RPMI 1640 medium supplemented with 10% fetal bovine serum (Gibco BRL, Gaithersburg, MD, USA). For the transcriptional activation assay, the medium was replaced with phenol-red-free RPMI 1640 medium supplemented with 5% charcoal-stripped fetal bovine serum when 25,000 cells were seeded per well in a 96-well plate. After culturing for 48 hours in a 37°C incubator, the cells were treated with momordin Ic, platycodin D2, polygalacin D, asiaticoside B, bacopaside I, notoginsenoside R2, pseudoginsenoside RT5, ladeanin A, or vinaginsenoside R4 along with 1 nM DHT as shown in Table 6. After culturing for another 24 hours, the extent to which the DHT-increased luciferase activity was inhibited was measured using a luciferase assay system (Promega). Results were calculated by setting the luminescence value increased by 1 M DHT treatment as 100% and the values ​​inhibited by momordin Ic, platycodin D2, polygalacin D, asiaticoside B, bacopaside I, notoginsenoside R2, pseudoginsenoside RT5, radeanin A, or vinaginsenoside R4. Bicalutamide (Casodex) was used as an anti-androgen positive control, and CCK-8 assays were performed in parallel to confirm cytotoxicity due to substance treatment. CCK-8 reagent was added to the culture medium at a 1:10 ratio and incubated for 2 hours. After 2 hours, the absorbance of each well was measured at 450 nm. All experiments were repeated three times, and the average absorbance value was calculated. The value of the 1 nM DHT-treated group was set to 100%, and the values ​​of the other treatment groups were calculated relative to this average.

[0048] [Table 6]

[0049] The experimental results showed that treatment with platycodin D2, polygalacin D or notoginsenoside R2 showed a high ability to suppress the action of androgens.

[0050] Experimental Example 5: Confirmation of hair growth effect of hair loss treatment / hair growth composition (hair tonic) The hair growth effect of the hair loss treatment / hair growth composition 1 (hair tonic) of the present invention was tested on a total of 190 men and women with weak hair, either with significantly fewer hairs than normal or with hair loss symptoms. The scalp areas of the 190 men and women were divided into left and right halves, and different compositions were applied to each halves. Twenty-five groups of 15 men and women were treated with Comparative Examples 1, 2, and 3 and Examples 1 to 11-2, which were applied to the hair and scalp five times a week for six months. After application, researchers evaluated the results using clinical photographs and phototrichograms. Researchers evaluated the Comparative and Examples 2 and 6 months after application, using clinical photographs to assess the results according to three criteria: "Good," "Slight," and "no change" (Good: 50% to 75% improvement; Slight: 25% to 50% improvement; no change: no change). The number of hairs per unit area and average hair thickness were evaluated using phototrichograms for the Comparative and Examples 6 months after application, and the results are shown in Table 7.

[0051] [Table 7]

[0052] As a result of the experiment, it was confirmed that Examples 1 to 11-2 containing momordin Ic, platycodin D2, polygalacin D, asiaticoside B, bacopaside I, notoginsenoside R2, picfertalaenin IB, pseudoginsenoside RT5, ladeanin A, vinaginsenoside R4, or diglycoside II exhibited high hair loss prevention and hair growth effects. In particular, the formulation containing ethanol demonstrated even higher hair loss prevention and hair growth effects. These results demonstrate that the composition for preventing hair loss and promoting hair growth of the present invention, which contains momordin Ic, platycodin D2, polygalacin D, asiaticoside B, bacopaside I, notoginsenoside R2, picfertalaenin IB, pseudoginsenoside RT5, ladeanin A, vinaginsenoside R4, or diglycoside II as an active ingredient, can be used very effectively in treating hair loss. It will be obvious to those skilled in the art that the above-mentioned dosage forms such as hair tonic or hair lotion are merely examples of the composition for preventing hair loss or promoting hair growth of the present invention, and the scope of the composition of the present invention is not limited to these dosage forms.

[0053] In addition, examples of shampoo compositions of the present invention are shown in Table 8 below, and examples of conditioner compositions are shown in Table 9 below.

[0054] [Table 8]

[0055] [Table 9]

Claims

1. A composition for preventing hair loss or promoting hair growth, comprising one or more active ingredients selected from the group consisting of picfertalaenin IB, radeanin A, and diglycoside II, in an amount of 0.0001 to 0.1% by weight based on the total weight of the composition.

2. The composition for preventing hair loss or promoting hair growth according to claim 1, wherein the composition promotes the activity of hair papilla cells.

3. The composition for preventing hair loss or promoting hair growth according to claim 1, wherein the composition promotes the activity of the Wnt / β-catenin signaling pathway in hair papilla cells.

4. 2. The composition for preventing hair loss or promoting hair growth according to claim 1, wherein the composition suppresses the action of male hormones.

5. A composition for preventing hair loss or promoting hair growth as described in claim 1, which is a pharmaceutical composition.

6. A composition for preventing hair loss or promoting hair growth as described in claim 1, which is a quasi-drug composition.

7. A composition for preventing hair loss or promoting hair growth as described in claim 1, which is a cosmetic composition.

8. A composition for preventing hair loss or promoting hair growth as described in claim 1, which is a product for hair or scalp.

9. 9. The composition for preventing hair loss or promoting hair growth according to claim 8, wherein the product is a hair or scalp product selected from the group consisting of hair growth agents, scalp cleansing agents, scalp scaling agents, scalp massage agents, scalp care agents, detergents, shampoos, tonics, hair conditioners, hair lotions, gels, packs, creams, essences, powders, sprays, oils, soaps, ointments, hair styling agents, hair dyes, and hair perm agents.

10. A composition for preventing hair loss or promoting hair growth as described in claim 1, which is a hair or health functional food composition.

Images